As with other H reductase inhibitors (statins), when therapy with moderate possible (more than 3 times the upper limit of normal increased serum activity of “liver” transaminases: Prior to initiation of therapy, after 6 weeks and 12 weeks after starting or after increasing the dose, liver function tests need to be monitored . Liver function should be monitored and the appearance of clinical signs of liver damage. In the case of increasing the activity of anadrol for women, their activity anadrol for women should be monitored as long as it is not normal. Should be used with caution in patients who abuse alcohol and / or have a history of liver disease (see. Section “Precautions”). Liver disease in the active stage or increased activity of “liver” transaminases blood plasma of unknown origin is a contraindication for use (sm. section “Contraindications”). Prevention of stroke by means of intensive lipid-lowering therapy. in a retrospective analysis of the various subtypes of stroke in people who do not have coronary heart disease , who recently had a stroke or transient ischemic attack, it was detected at higher risk of hemorrhagic stroke patients receiving atorvastatin 80 mg compared with placebo. Particularly high risk observed in patients after a hemorrhagic stroke or lacunar infarct at study entry. For patients who have had a hemorrhagic stroke or lacunar infarction and receiving atorvastatin 80 mg, risk / benefit ratio is ambiguous, and should carefully assess the potential risk of hemorrhagic stroke before treatment may be assumed in patients with diffuse myalgia, muscle tenderness or weakness and / or marked increase in activity . Treatment should be discontinued in the event expressed increasing or in the presence of confirmed or suspected myopathy. When using other inhibitors of HMG-Co reductase inhibitors (statins) may increase the risk of myopathy with the concomitant use of cyclosporine, fibrates, erythromycin, nicotinic acid lipid-lowering doses (more than 1 g / d) or azole antifungals. Applying medication anadrol for women in combination with fibrates, erythromycin, immunosuppressants, azole antifungals or niacin in lipid-lowering doses (more than 1 g / day), you need to weigh the potential benefits and risks of treatment . Very rarely reported cases of immune-mediated necrotising myopathy during or after the treatment with statins, including atorvastatin.
Immune-mediated necrotizing myopathy is clinically characterized by muscle weakness in the upper extremities and the increased concentration of plasma, persisting despite the discontinuation of statin treatment. If necessary, combination therapy should consider the use of these drugs at lower initial and maintenance doses. It is recommended periodic monitoring of the activity . The combined use of atorvastatin and fusidic acid is not recommended, therefore, to consider the suspension of atorvastatin during the use of fusidic acid. Patients should be warned that you must immediately consult a doctor if unexplained aches or muscle weakness, particularly if accompanied by malaise or fever! In applying the anadrol for women other inhibitors of reductase inhibitors (statins) are described rare cases of rhabdomyolysis with acute renal failure due to myoglobinuria. If you have symptoms of possible myopathy or presence of renal failure factor risk against the background of rhabdomyolysis (eg, severe acute infection, hypotension, major surgery, trauma, metabolic and endocrine disorders, and uncontrolled seizures) therapy should suspend or cancel. interstitial lung disease has been reported on the extremely rare cases of interstitial lung disease with the use of some statins, especially with prolonged therapy.
Clinical manifestations include dyspnea, non-productive cough and deterioration in general health (fatigue, weight loss and fever). If it is suspected to develop interstitial lung disease, statin therapy should be discontinued. Diabetes Some studies suggest that the use of statins, as a class, can lead to increased blood glucose levels, and in some patients with an increased risk of developing diabetes in the future It can cause the level of hyperglycemia in which the required standard antidiabetic therapy. However, such a risk is negligible in comparison with a reduction in cardiovascular risk statins and therefore should not cause withdrawal of treatment with anadrol for women statins. Patients at riskshould be under control, as the clinical and biochemical, in according to national standards of care.